Table 3. Therapy switching in the mono-therapy group and combination group.
| Treatment group | Follow-up (month) |
||||
|---|---|---|---|---|---|
| 0 | 6 | 12 | 24 | 42 | |
| Mono-therapy group | |||||
| • Mono-therapy remained unchanged, n (%) | 32,682 (100.0) | 13,789 (83.3) | 11,248 (76.6) | 8,845 (67.8) | 2,749 (59.7) |
| • Most commonly used drug in the mono-therapy (%) | CCB (52.1) | CCB (44.6) | CCB (41.0) | CCB (36.3) | CCB (33.3) |
| • Switching from mono-therapy to dual combination therapy, n (%) | 0 (0.0) | 1,161 (7.0) | 1,520 (10.4) | 2,141 (16.4) | 1,047 (22.7) |
| • Switching from mono-therapy to traditional Chinese drugs/proprietary Chinese medicines or use of ≥3 antihypertensive drugs, n (%) | 0 (0.0) | 1,604 (9.7) | 1,914 (13.0) | 2,059 (15.8) | 812 (17.6) |
| • Most commonly used drug after therapy switching (%) | – | Traditional Chinese drugs (9.2) | Traditional Chinese drugs (12.0) | Traditional Chinese drugs (15.2) | Traditional Chinese drugs (14.0) |
| Combination group | |||||
| • Dual combination therapy remained unchanged, n (%) | 4,926 (100.0) | 1,853 (69.2) | 1,586 (64.0) | 1,205 (58.6) | 346 (56.4) |
| • Most commonly used drug in the dual combination therapy (%) | CCB + ARB (39.2) | CCB + ARB (34.3) | CCB + ARB (34.3) | CCB + ARB (32.2) | CCB + ARB (31.6) |
| • Switching from dual combination therapy to mono-therapy, n (%) | 0 (0.0) | 581 (21.7) | 620 (25.0) | 535 (26.0) | 159 (25.9) |
| • Switching from dual combination therapy to traditional Chinese drugs/proprietary Chinese medicines or use of ≥3 antihypertensive drugs, n (%) | 0 (0.0) | 245 (9.2) | 272 (10.9) | 317 (15.4) | 109 (17.8) |
| • Most commonly used drug after therapy switching (%) | CCB (7.8) | CCB (10.7) | CCB (12.2) | CCB (15.3) | CCB (7.8) |
Note: CCB, calcium channel blockers; ARB, angiotensin II receptor blockers; ACEI, angiotensin converting enzyme inhibitor.